EN DE
Watch Diamyd Medical AB (publ) for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Diamyd Medical AB (publ) (DMYD-B) fair value: what the stock is really worth

As of Oct 19, 2026: fair value (intrinsic value) of Diamyd Medical AB (publ) stock SEK 1.23, price SEK 1.01, upside +21.6%, quality 25 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE · ISIN SE0005162880

DM Diamyd Medical AB (publ) logo Thin data Oct 3, 2026

Diamyd Medical AB (publ)

DMYD-B · ST

SpeculativeUpside exists, but weak quality makes the signal speculative.

The stock costs 18% less than our calculation considers fair.

Fair value kr 1.23 · Undervalued (+21.6%)
Low debt
Mixed Growth (revenue 3y −34.1 %/yr in SEK)
Mixed vs. peers (3/7)
Quality 25/100
Negative free cash flow
Narrow moat 9/100
Thin data
⚠ Dilution
Watch Diamyd Medical AB (publ) for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 38.08 kr 0.9420 Fair Value kr 1.23 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range kr 0.9420 – kr 38.08 · fair‑value band kr 0.8160 – kr 1.54 · the kr 1.01 price screens below the kr 1.23 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow Diamyd Medical AB (publ) in your weekly email

Every Wednesday you see whether Diamyd Medical AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes.

Show moreShow less

The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes.

Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is headquartered in Stockholm, Sweden.

Stock analysis

Diamyd Medical AB (publ) (DMYD-B) currently trades at kr 1.01, while our model-based Fair Value estimate is kr 1.23, implying the stock looks roughly 17.8% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: kr 0.8160 (bear) to kr 1.54 (bull), the price of kr 1.01 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2021: revenue and profit before it include the divested business. Growth is measured afresh from 2021.

Diamyd Medical AB (publ) reported revenue of 130K SEK in FY2025 versus 253K SEK in FY2021, a compound −15.3%/yr. Reported net income was −170M SEK in FY2025.

Key figures

Market cap 153M SEK (≈ $15.4M) Micro · EPS (TTM) kr −2.00 · Return on equity −97.1% · Return on assets (EBIT) −54.2% · Operating margin −181,711% · Revenue growth (YoY) +15.1% · EPS growth (YoY) −59.4% · Free cash flow −180M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 94% below its 52-week high and 8% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 22%, DMYD-B screens cheaper than that median.

Fair Value models

Bear kr 0.8160 Fair Value kr 1.23 Bull kr 1.54
Price kr 1.01 · Upside +21.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 0.9600 kr 1.45 kr 1.81 55
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.9600 kr 1.45 kr 1.81 55

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 27
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Momentum 17
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2021: revenue and profit before it include the divested business. Growth is measured afresh from 2021.
Revenue growth 1 year
+0.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2,856.0% (2020) → −140,950.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch DMYD-B, get fair value alerts →

Compare Diamyd Medical AB (publ) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 604 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside +21.5% · Top 25%
Profitability
Return on assets −48.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 15.1% · Above median
Balance sheet
Debt / equity 0.16× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.54× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)62 · sector 0
FUTURE (revenue growth)76 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)92 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $746.54 $1,275 +71% vs DMYD-B
Vertex Pharmaceuticals Incorporated VRTX $510.08 $561.09 +10% vs DMYD-B
argenx SE ARGX $825.03 $907.53 +10% vs DMYD-B
Samsung Biologics Co 207940 1,298,000 KRW 1,427,800 KRW +10% vs DMYD-B
WuXi Biologics (Cayman) Inc 2269 HK$52.65 HK$57.92 +10% vs DMYD-B
CSL Limited CSL A$192.20 A$180.83 −6% vs DMYD-B
Alnylam Pharmaceuticals, Inc ALNY $232.68 $217.88 −6% vs DMYD-B
BeOne Medicines AG ONC $354.47 $280.94 −21% vs DMYD-B
Celltrion, Inc 068270 180,400 KRW 74,519 KRW −59% vs DMYD-B
Royalty Pharma plc RPRX $56.93 $19.01 −67% vs DMYD-B

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Diamyd Medical AB (publ) · Fair Value
kr 1.23 +18%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Diamyd Medical AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/DMYD-B

Frequently asked questions

Is Diamyd Medical AB (publ) (DMYD-B) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of kr 1.23 versus a price of kr 1.01, about +22% upside (undervalued).
What is the fair value of DMYD-B?
Our model-based fair value for Diamyd Medical AB (publ) is kr 1.23 (as of Oct 3, 2026), built from audited fundamentals. The current price: kr 1.01.
What is the quality score of DMYD-B?
Diamyd Medical AB (publ) has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Diamyd Medical AB (publ) (DMYD-B)?
Our model-based price target is the fair value of kr 1.23 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario kr 0.8160, optimistic scenario kr 1.54. It is a calculation from audited fundamentals, not an analyst target.
What is the Diamyd Medical AB (publ) stock forecast for 2026?
Our models put fair value at kr 1.23, about +22% upside versus a price of kr 1.01 (undervalued). Cautious scenario kr 0.8160, optimistic scenario kr 1.54. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Diamyd Medical AB (publ) (DMYD-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Diamyd Medical AB (publ) it is kr 1.23 per share (as of Oct 3, 2026), against a price of kr 1.01. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Diamyd Medical AB (publ) stock overvalued or undervalued in 2026?
As of Oct 3, 2026, DMYD-B trades below its calculated fair value: price kr 1.01, fair value kr 1.23, a gap of about +22% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DMYD-B?
No. The price is what the market pays today (kr 1.01); the fair value is what the company's own numbers justify (kr 1.23). For Diamyd Medical AB (publ) the two are kr 0.2190 per share apart. That gap is exactly why we show both numbers side by side.
How much is Diamyd Medical AB (publ) worth?
The market values Diamyd Medical AB (publ) at about 153M SEK (market capitalisation, as of Oct 3, 2026). Per share that is kr 1.01; our models calculate a fair value of kr 1.23 per share.
What do the bullish and bearish scenarios say about DMYD-B?
Our models span a range for Diamyd Medical AB (publ): cautious scenario kr 0.8160, base kr 1.23, optimistic kr 1.54 per share (as of Oct 3, 2026, price kr 1.01). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Diamyd Medical AB (publ) (DMYD-B)?
Balance-sheet figures for Diamyd Medical AB (publ) (as of Oct 3, 2026): return on equity −97.1%, debt of 0.16 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is DMYD-B from its 52-week high?
Diamyd Medical AB (publ) trades at kr 1.01, about 94% below its 52-week high of kr 17.62 and 8% above the low of kr 0.9420 (as of Oct 19, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.23 is for.
Which stocks are comparable to Diamyd Medical AB (publ)?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Diamyd Medical AB (publ) stock attractive at the current price?
The data as of Oct 3, 2026: price kr 1.01, calculated fair value kr 1.23 (+22%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DMYD-B calculated?
We run Diamyd Medical AB (publ) through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 1.23, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Diamyd Medical AB (publ) currently trades 18 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Diamyd Medical AB (publ) (DMYD-B)?
The closing price on Oct 19, 2026 was kr 1.01. Our model-based fair value is kr 1.23, about +22% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Diamyd Medical AB (publ) right now?
A fairly wide model range (kr 0.8160 to kr 1.54) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Diamyd Medical AB (publ)

How large is the market capitalisation of Diamyd Medical AB (publ) (DMYD-B)?
The market capitalisation of Diamyd Medical AB (publ) is 153M SEK (≈ $15.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Diamyd Medical AB (publ) (DMYD-B)?
Earnings per share at Diamyd Medical AB (publ) are kr −2.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Diamyd Medical AB (publ) (DMYD-B)?
The return on equity (ROE) of Diamyd Medical AB (publ) is −97.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Diamyd Medical AB (publ) (DMYD-B)?
On an EBIT basis the return on assets of Diamyd Medical AB (publ) is −54.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Diamyd Medical AB (publ) (DMYD-B)?
The operating margin of Diamyd Medical AB (publ) is −181,711% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Diamyd Medical AB (publ) (DMYD-B)?
Revenue at Diamyd Medical AB (publ) is growing +15.1% versus a year earlier (3y avg −34.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Diamyd Medical AB (publ) (DMYD-B)?
Earnings per share at Diamyd Medical AB (publ) are growing −59.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Diamyd Medical AB (publ) (DMYD-B) generate?
The free cash flow of Diamyd Medical AB (publ) is −180M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Diamyd Medical AB (publ) (DMYD-B) hold?
Diamyd Medical AB (publ) holds more cash than debt, 277M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Diamyd Medical AB (publ) in the live analysis

One click puts Diamyd Medical AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.